40th Pharmacovigilance UK & EU 2026

LONDON, 2025-11-12 — /EPR Network/ — 11 & 12 March 2026, Sheraton Skyline, Heathrow, London, UK
This event will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. Take a chance and make it count by attending our event to network with your peers, exchange expertise and experiences, and arm yourself with the latest information to take your department to the next level. It gives me great pleasure in welcoming all of you to the Virtue Insight’s 40th Pharmacovigilance UK & EU 2026. I wish and pray that all our efforts will be beneficial to our industries and to our all at large.
Please contact Kavitha at E-mail – kavitha@virtueinsight.co.in or call +44 20 3509 3779
DELEGATE REGISTRATION:
SUPER EARLY BIRD PRICE (Valid until 11 December 2025)
1 Delegate @ £ 799 + VAT
Group Discount @ £ 1598 + VAT (3 Delegates for the price of 2)
EARLY BIRD PRICE (Valid until 12 Dec 2025 -6 Feb 2026)
1 Delegate @ £ 999 + VAT
Group Discount @ £ 1998 + VAT (3 Delegates for the price of 2)
STANDARD PRICE ( From 7 Feb 2026)
1 Delegate @ £ 1299 + VAT
Group Discount @ £ 2598 + VAT (3 Delegates for the price of 2)
SPONSORS:
Platinum Sponsor – AridGlobal
We have sponsorship opportunities available for the event, which gives you an opportunity to speak/exhibit, and create brand awareness. Here you can have a dedicated networking time, meet the leading international vendors and expand your knowledge of the latest business models. Please email to kavitha@virtueinsight.co.in for more details.
KEY SPEAKERS:
• KARSTEN LOLLIKE, Scientific VP, Deputy QPPV, Global Patient Safety, Novo Nordisk
• STEPHANIE MILLICAN, Deputy Director BRE II, MHRA
• MICHAEL BEAN, Senior Director, Regulatory Compliance, Johnson & Johnson
• FELIX ARELLANO, Senior VP and Global Head of Safety & Risk Management, Roche
• CHETAN SHATAPATHY, Executive Director & Head, ADC Group, Patient Safety Oncology, AstraZeneca
• AZZA ELGHARABLY, Associate Director, Patient Safety Scientist, AstraZeneca
• LEONA HOUGHTON, Vice President, Global Safety (Ex-US), Mundipharma
• MIRCEA CIUCA, Independent PV Consultant / International PV Expert (Former Global Head Medical Safety, Organon)
• MIJAL CHAVDA, Senior Director, Global Head of GxP Inspections & GVP Quality, Kyowa Kirin
• REMCO M. DIAB, Sr. Dir. Lead Global Safety Officer Immunology & Inflammation, Sanofi
• GYORGY ZORENYI, Senior Medical Director, Medical Safety, Jazz Pharma
• VALENTINA MANCINI, Senior Director Pharmacovigilance, QPPV, Shionogi Europe
• CHRISTIAN MUHL, Senior Director Compliance, GSK
• PAV RISHIRAJ, Director, Head of Pharmacovigilance, Ipsen
• CALVIN JOHNSON, Executive Director & Head of International Patient Safety, Bristol-Myers Squibb
• LEA GALOVIC, Associate Director¸ Risk Management,, Global Patient Safety & PV, Teva
• YVONNE NANCIU, Country Head Pharmacovigilance Deputy EU QPPV, Bayer
• TEA BABIC, Director, PV Audits & Inspections, Teva
• TERESA SARAGOCA, Director, Regulatory Affairs & Technical Manager, ITALFARMACO
• SABINE POLTERMANN, Head of Country Patient Safety Switzerland, Bristol-Myers Squibb
• JOHN SOLOMON, Former Head of Pharmacovigilance – UK & Ireland, Sanofi
• BEGUM BENLI PEKER, Head of Patient Safety EU Hub, Bristol-Myers Squibb
• SIMON ASHWORTH, Head of Pharmacovigilance & Medical Safety, MENARINI Group
• SUMIT MUNJAL, Global Head of Medical Safety, Otsuka Pharmaceuticals
• RISHI CHOPRA, Head of International PV & Global PV Operations | Dep. UK QPPV, CSL Behring
• PHILLIP EICHORN, Global Head of Drug Safety, Amryt Pharma
• GALINA CORDERO, Head of Pharmacovigilance Dept, QPPV, JSC Farmak
• WOLF HENNING, GEBHARDT, R&D Scientist Advanced Analytics, Abbott
• ABIDALI FAZAL, Safety Science Director, Roche
• MARJAN DZEPAROSKI, Head of Regulatory Affairs, Drug Safety & Intelectual Property, Bionika Pharmaceuticals
• RUDI SCHEERLINCK, Safety Strategy Lead – Oncology, Healthcare Business of Merck
• MICHAEL VON FORSTNER, Chief Scientific Officer, MedGenie
• RAGHDA MOHAMED, Patient Safety Cluster Lead – Middle East & Turkey / Global patient Safety Evaluation, Takeda Pharmaceuticals
• GAURI UTTURKAR, Benefit Risk Lead (Associate Director), UCB
• LEONARDO PEREIRA, Clinical Safety Director, Roche
• ARUN RAVINDRAN, Benefit Risk Lead (Late phase Clinical Development Safety), UCB
• ZINA SADEQ, Director, Regional PV & Alliance Management, UK QPPV, Amicus Therapeutics
• CINTHYA GALICIA QUINTANAR, Senior Manager, Country Safety Lead, Pfizer
• SANJEEV SRIVASTAV, Signal Management Lead, BioNTech
Plus more joining soon
KEY THEMES DISCUSSED THIS YEAR:
• CHALLENGES / OPPORTUNITIES
• PATIENT SAFETY
• RMP/ REMS
• SAFETY & SIGNAL DETECTION
• AUTOMATION IN PV
• REGULATORY
• MEDICAL DEVICES
• IMPACT OF TECHNOLOGY AI, ML
• AUDITS & INSPECTION
• RWE / RWD
• OUTSOURCING
• MARKET TRENDS – CRITIQUES & WAYS FORWARD
WHO SHOULD ATTEND:
CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Mgr’s, Scientific Advisors, Consultants of:
Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information & Clinical Data Management, Clinical Pharmacology, Clinical Safety, PSURs, RMP / REMS, RWE / RWD, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs & Compliance, Information technology, Sales & Marketing
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.